This site is intended for health professionals only

At the heart of general practice since 1960

Ablation effective second-line treatment in long-standing PAF

Cardiovascular medicine

Cardiovascular medicine

?There is currently much interest in radio-frequency ablation as a potentially curative procedure in atrial fibrillation (AF). Good evidence exists to support the use of radio-frequency pulmonary vein ablation in patients with a new presentation of paroxysmal atrial fibrillation (PAF), but the role of ablation in long-standing PAF is less clear. However, new evidence suggests that ablation may be an effective second-line strategy in patients with long-standing PAF.

The APAF study, although relatively small because of its highly specialised content, compares pulmonary vein ablation with antiarrhythmic drug therapy in patients with PAF. The study recruited 198 patients, with PAF of 6 ± 5 years' duration with a mean occurrence of 3.4 episodes/month, who had already failed to achieve control on one antiarrhythmic drug. They were randomised to either an ablation strategy or an alternative antiarrhythmic drug (including flecainide, sotalol and amiodarone).

The results were very encouraging, with 93 per cent of the ablation group free of recurrence compared with only 35 per cent of the drug group at one year. In the drug group, hypertension, ejection fraction and age independently predicted AF recurrence, and 23 patients had side-effects. In the ablation group there was one case of transient ischaemic attack and one case of pericardial effusion.

In patients with long-standing symptomatic PAF the initial priority is to administer appropriate thromboprophylaxis. However, in patients who fail to respond to antiarrhythmic drug therapy (and/or a standard ß-blocker), referral to an electophysiologist for consideration of ablation can be a more effective treatment strategy than switching to an alternative antiarrhythmic agent.

Pappone C, Augello G, Sala S, et al. A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation J Am Coll Cardiol 2006;48:2340-7

Reviewer

Dr Peter Savill
GPSI Cardiology, Southampton

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say